Outcomes for different clinical subtypes in doxofylline group and non‐doxofylline group, per‐protocol population
SECONDARY
Primary outcome (severe exacerbation) data for all 6 months of follow‐up were available for all 155 participants (68 in the DG; 87 in the NDG) (Table Outcomes for participants to doxophylline group and non‐doxophylline group, per‐protocol population.There was a clinically significant difference between DG and NDG.The outcomes for the participants in the doxofylline group (DG) and the non‐doxofylline group (NDG).For the secondary outcomes of FEVOutcomes for participants to doxophylline group and non‐doxophylline group, clinical phenotypes, per‐protocol population.There was a clinically significant difference between DG and NDG.Outcomes for participants to doxophylline group and non‐doxophylline group, clinical phenotypes, per‐protocol population.There was a clinically significant difference between DG and NDG.The incidence rates of exacerbations for each clinical subtype at the first, third, and sixth months compared with the baseline.